Article



An N-Terminal Mutation of the Foxp3 Transcription Factor Alleviates Arthritis but Exacerbates Diabetes

Jaime Darce,¹ Dipayan Rudra,² Li Li,¹ Junko Nishio,¹ Daniela Cipolletta,¹ Alexander Y. Rudensky,² Diane Mathis,^{1,*} and Christophe Benoist^{1,*}

¹Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA

²Howard Hughes Medical Institute and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA *Correspondence: cbdm@hms.harvard.edu

DOI 10.1016/j.immuni.2012.04.007

SUMMARY

Maintenance of lymphoid homeostasis in a number of immunological and inflammatory contexts is served by a variety of regulatory T (Treg) cell subtypes and depends on interaction of the transcription factor FoxP3 with specific transcriptional cofactors. We report that a commonly used insertional mutant of FoxP3 (GFP-Foxp3) modified its molecular interactions, blocking HIF-1a but increasing IRF4 interactions. The transcriptional profile of these Treg cells was subtly altered, with an overrepresentation of IRF4-dependent transcripts. In keeping with IRF4dependent function of Treg cells to preferentially suppress T cell help to B cells and Th2 and Th17 cell-type differentiation, GFP-FoxP3 mice showed a divergent susceptibility to autoimmune disease: protection against antibody-mediated arthritis in the K/BxN model, but greater susceptibility to diabetes on the NOD background. Thus, specific subfunctions of Treg cells and the immune diseases they regulate can be influenced by FoxP3's molecular interactions, which result in divergent immunoregulation.

INTRODUCTION

The transcription factor FoxP3 plays a central role in specifying the differentiation and function of regulatory T (Treg) cells. FoxP3⁺ Treg cells help maintain lymphoid homeostasis in a number of immunological contexts: tolerance to self versus autoimmune deviation, responses to pathogens or allergens, and interactions with commensal microbes (Campbell and Koch, 2011; Barnes and Powrie, 2009; Feuerer et al., 2009b). The importance of FoxP3⁺ Treg cells is highlighted by the devastating multiorgan inflammation of FoxP3-deficient *scurfy* mice or human IPEX patients (Ziegler, 2006). In addition, FoxP3⁺ Treg cells partake in extraimmune regulatory activities, for instance by dampening inflammation and metabolic activity in visceral adipose tissue (Feuerer et al., 2009a).

Several pathways and molecular mediators of Treg cell function have been described—some involving cell-cell interactions, others soluble cytokines or small-molecule mediators (Vignali et al., 2008; Shevach, 2009). Correspondingly, a number of Treg cell subphenotypes exist, with differential effector functions and tissue localization (Feuerer et al., 2009a; Feuerer et al., 2010; Campbell and Koch, 2011). Although Treg cells generally share a transcriptional program that distinguishes them from conventional CD4⁺ (Tconv) cells, this program is modified and tuned in relation to Treg cell function. For instance, Treg cells in the adipose tissue express a set of transcripts reflective of homing and adaptation to the adipose environment and to the functions they exert there (Feuerer et al., 2009a and data not shown). These programs appear to be determined in Treg cells by the same transcription factors that are central to the differentiated functions of the Tconv cells they regulate. For instance, IRF4 is required for the differentiation of B cells and of the T helper 2 (Th2)-type cells that help them, and the absence of IRF4 in Treg cells impairs their ability to control Th2 cell responses and antibody production (Zheng et al., 2009). Similarly, Treg cells expressing T-bet or STAT3 transcription factors optimally suppress inflammatory Th1 and Th17 cell responses, respectively (Koch et al., 2009; Chaudhry et al., 2009).

Underscoring this specialization of Treg cell functionalities, FoxP3 engages in a number of interactions with other transcription factors (Xiao et al., 2010). Through its leucine zipper region, FoxP3 can dimerize with itself or with other forkhead domain proteins (Lopes et al., 2006; Li et al., 2007b) and can homodimerize through the formation of a peculiar domain-swapped dimer of the DNA-binding forkhead domain (Bandukwala et al., 2011). FoxP3 interacts with the transcription factors Runx1, NF-AT, Eos (encoded by *lkzf4*), IRF4, ROR γ t, ROR α , and phosphorylated STAT3 (Ono et al., 2007; Wu et al., 2006; Pan et al., 2009; Zheng et al., 2009; Zhou et al., 2008; Chaudhry et al., 2009). Several of these interactions have been linked to a particular facet of the Treg cell transcriptional profile; for instance, IRF4 or STAT3 subtly affect, alone or in combination with FoxP3, discrete segments of the Treg cell signature (Zheng et al., 2009; Chaudhry et al., 2009).

This diversity of Treg cell subphenotypes and interacting facets of FoxP3 suggests that shifts in these interactions, occurring physiologically or experimentally, should modulate the range of Treg effector abilities. Here, we report such a situation, where a modification of FoxP3 results in diametrically opposite effects on the severity of different autoimmune diseases.

RESULTS

Divergent Autoimmune Phenotypes in Mice Carrying the *Foxp3^{fgfp}* Knockin

Our initial observations were made serendipitously in the course of analyzing the role of FoxP3⁺ Treg cells in the K/BxN model of



Immunity

Different Treg Cell Functions in Autoimmunity



Figure 1. Foxp3^{fgfp} Mice Exhibit Contrasting Phenotypes in Different Autoimmune Models

(A) Schematic representation of FoxP3, GFP-FoxP3, and FoxP3-I-GFP. Protein convertase cleavage sites (RXXR), proline-rich regions (Pxxp1 and Pxxp2), and leucine zipper (Leu-zip) and forkhead (FKH) domains are represented.

(B) Arthritis clinical score and ankle measurements of 8-week-old K/BxN.Foxp3^{/g/p} males, K/BxN.Foxp3^{/g/p/wt} heterozygote females, and WT littermate control mice.

(C) Anti-GPI IgG reactivity in sera of 8-week-old K/BxN.Foxp3^{/g/p} males, K/BxN.Foxp3^{/g/p/wt} females, and WT littermate control mice (mean ± SD, n = 6-8).

(D) Arthritis clinical score, ankle thickness, and anti-GPI antibodies in 8-week-old male and female K/BxN.Foxp3^{/gtp} and WT controls (mean ± SD, n = 6-8).

(E) Diabetes incidence curves of NOD.*Foxp3*^(gfp) males NOD.*Foxp3*^(gfp/wt), females and littermate controls (10 mice/group). Two different cohorts of NOD.*Foxp3*^(gfp/wt) heterozygous females were followed, in two different animal facilities.

inflammatory arthritis. These mice carry the KRN transgene, which encodes a T cell receptor (TCR) reactive against a peptide from the ubiquitous enzyme, glucose-6-phosphate isomerase (GPI), presented by the MHC class II molecule A^{g7} (Kouskoff et al., 1996). When the KRN transgene is crossed into an A^{g7} -positive genetic background, autoreactive T cells promote the massive production of anti-GPI IgG, which rapidly and spontaneously induce arthritis. They can also provoke arthritis after transfer into normal recipients (Korganow et al., 1999). To help identify Treg cells in arthritic mice, we introduced into K/BxN mice the *Foxp3^{gfp}* (*Foxp3^{tm2Ayr}*) reporter knockin from Fontenot et al. (2005), in which the eGFP coding region is inserted in-frame

into the coding region of the *Foxp3* locus on the X chromosome, yielding a functional chimeric fusion protein with GFP inserted between amino acids 5 and 6 of FoxP3 (Figure 1A; the locus encoding this fusion protein will be referred to as *Foxp3*^{fgfp}). It is distinguished from the bicistronic ires-driven reporter *Foxp3*^{igfp} of Bettelli et al. (2006), in which GFP is not fused with FoxP3 but is concomitantly expressed from a bicistronic mRNA, leaving FoxP3 intact, and which was used as a control throughout this study.

We noticed that the presence of the *Foxp3^{fgfp}* reporter modified considerably the course of K/BxN arthritis. Males developed no or very mild arthritis, as judged by both ankle thickening and

Immunity

Different Treg Cell Functions in Autoimmunity



Figure 2. Foxp3^{fgfp} Disease Phenotype Does Not Correlate with an Alteration in Treg Cell Frequency

(A and B) Percentage of FoxP3-positive cells within CD4⁺ T cells.

(A) Spleens and draining lymph nodes (popliteal) of 8-week-old WT and K/BxN.Foxp3^{rg/p} males (each point is an individual mouse).

(B) Spleen and pancreas of 9-week-old NOD.Foxp3^{fgfp} males and controls.

(C) Proportion of FoxP3⁺ Treg cells among LN and visceral adipose tissue of 40-week-old B6 males.

(D) Representative dot plots showing the percent FoxP3⁺ Helios⁻ Treg cells in colon lamina propria and spleen of 6-week-old B6.*Foxp3^{fgfp}* and B6.*Foxp3^{igfp}* males.

(E) Splenocytes from K/BxN.*Foxp3*^{(gfp/wt} heterozygote females were stained with CD3, CD4, and FoxP3 antibodies. Gates and values represent the fraction of GFP-positive and -negative cells among FoxP3⁺ population. A summary of data in adjacent plot shows a fraction of GFP⁺ cells among FoxP3⁺ cells in the thymus, spleen, and draining lymph nodes of K/BxN.*Foxp3*^{(gfp/wt} females; the dashed line denotes the 50/50 ratio expected from random X-chromosome inactivation. (F) Linear regression analysis of serum anti-GPI levels versus the fraction of GFP⁺ FoxP3⁺ Treg cells in K/BxN.*Foxp3*^{(gfp/wt} heterozygote females.

clinical index (Figure 1B). Protection in females was less extreme, with a delay in disease onset (Figure S1A available online) and variable severity. K/BxN.Foxp3^{fgfp} males had low to undetectable amounts of arthritogenic anti-GPI, in contrast to serum of K/BxN littermates (Figure 1C), K/BxN.Foxp3^{fgfp} heterozygote females also showed a significant reduction in anti-GPI, albeit less dramatic; these titers correlated well with arthritis severity (Figure S1A). These data imply that protection from arthritis in K/BxN.Foxp3^{fgfp} mice stemmed from a block in autoantibody formation, suggesting an active suppression of the immunologic phase of this model. This idea was further substantiated by the fact that B6.Foxp3^{fgfp} animals were sensitive to arthritis induced by transfer of arthritogenic K/BxN serum (Figure S1B). To address the possibility that protection from arthritis was simply due to GFP expression, we used the FoxP3-ires-GFP reporter line (Bettelli et al., 2006). K/BxN.Foxp3^{igfp} mice developed anti-GPI and arthritis as usual (Figure 1D), ruling out this interpretation.

Given this protection from arthritis, we next examined whether mice expressing GFP-FoxP3 would also be protected from other autoimmune diseases. Thus, the *Foxp3*^{fgfp} knockin was backcrossed for 12 generations to the NOD/Lt strain, the prototypical model of autoimmune type-1 diabetes (T1D), and evaluated through the course of diabetes. Surprisingly, the opposite result was obtained: whereas male NOD mice are usually resistant to diabetes, NOD.*Foxp3*^{fgfp} males showed a very high incidence of diabetes (Figure 1E). Similarly, NOD.*Foxp3*^{fgfp} heterozygote females exhibited an acceleration of diabetes, in two independent cohorts; some animals became diabetic before 10 weeks of age, which is never seen in our NOD colony.

Foxp3^{fgfp} Treg Cells Impact Disease Independent of Frequency

Because FoxP3 is exclusively expressed in Treg cells and conditions their differentiation and maintenance, we first examined whether differences in Treg cells between mice expressing GFP-FoxP3 might account for the contrasting phenotypes in the two autoimmune models. Flow cytometric analyses first focused on male mice, in which the Foxp3^{fgfp} phenotypes were most obvious, and on the spleen, where most of the anti-GPI of K/BxN mice are produced. No increase in the fraction of FoxP3⁺ among CD4⁺ splenocytes was observed in K/BxN.Foxp3^{fgfp} relative to K/BxN male mice (Figure 2A), as might have been expected from the suppression of disease. Instead, there was a decrease in the frequency of Treg cells, in mice expressing GFP-FoxP3, most significantly in the lymph nodes. A similar trend to decreased Treg cell frequency was observed in spleens of NOD.Foxp3^{fgfp} mice; however, this observation did not extend to the pancreas (Figure 2B). Thus, the difference in disease severity imparted by Foxp3^{fgfp} in these two models does not correlate with altered proportions of Treg cells in the key organs.

In view of the impact of the chimeric GFP-FoxP3 on distinct Treg cell populations, we investigated whether other Treg cell pools might be similarly affected. We have recently described a particular population of $FoxP3^+CD4^+$ T cells that resides in



Immunity

Different Treg Cell Functions in Autoimmunity



Figure 3. Decrease in Th17 Cells in K.BxN.Foxp3^{fgfp} Mice Is Independent of Inherent Th17 Cell Differentiation Defect (A) IL-17a-producing cells in spleen and small intestine lamina propria from 4- to 5-week old K/BxN and K/BxN.Foxp3^{fgfp} male mice. Gates and values represent fraction of IL-17a-positive cells in CD4 population. Data are summarized in adjacent graph. Data are representative of three independent experiments. (B) In vitro Th17 and Treg cell differentiation of congenically marked naive cells from WT (CD45.1) and Foxp3^{fgfp} (CD45.2) B6 mice. Data is representative of two independent experiments.

the abdominal adipose tissue, has a distinctive TCR repertoire and transcriptional profile, and impacts metabolic parameters (Feuerer et al., 2009a). In aged males, in which this population is most abundant, mice expressing GFP-FoxP3 showed a marked reduction in numbers of fat Treg cells (Figure 2C).

Another recently described Treg cell population is found in the colonic mucosa, induced by exposure to components of the gut microbiome, in a particular Clostridia species (Atarashi et al., 2011). This population differs from Treg cells in secondary lymphoid organs by not expressing the transcription factor Helios (encoded by *lkzf2*), which has been suggested to identify thymus-derived Treg cells (Thornton et al., 2010), although the correlation is probably not absolute (data not shown). We evaluated the representation and Helios expression of FoxP3⁺ Treg cells in the colonic lamina propria (LP) of B6.Foxp3^{fgfp} males. Significantly, more Foxp3^{fgfp} Treg cells lacked Helios than did Treg cells from B6.Foxp3^{igfp} or unmodified B6 mice, but no difference was observed in splenic Treg cells (Figure 2D). These results suggest that there may be an increased conversion to a Treg cell phenotype in the colon of Foxp3^{fgfp} mice in response to local microbiota.

In heterozygous female mice, we noted a significant imbalance in the fraction of FoxP3⁺ cells expressing the Foxp3^{fgfp} knockin allele. Random X inactivation should result in equivalent representation of Foxp3 alleles from both chromosomes, unless one conferred a particular advantage or disadvantage to the cells expressing it. This ratio of GFP⁺/GFP⁻ among FoxP3⁺ cells was skewed in splenic Treg cells of most K/BxN.Foxp3^{fgfp} females (Figure 2E), variably in individual mice, and ranging down to 1:4 (Figure 2E). This disproportion was evident early in differentiation of the Treg cell lineage in the thymus, probably reflecting a lower efficacy of selection. This thymic imbalance was most evident in K/BxN.Foxp3^{fgfp} females, perhaps because of their self-reactive TCR, given that it was more discrete in nontransgenic B6 and NOD females (data not shown). We used this variability to our advantage by assessing whether there was a relationship between percent Foxp3^{fgfp} Treg cells and anti-GPI titers. Indeed, anti-GPI titers were inversely correlated

with the proportion of GFP^+ cells among Treg cells in K/BxN females (Figure 2F).

Thus, the GFP-FoxP3 protein seems to alter in opposite ways the selection or stability of Treg cells that express it. But, whether comparing males to females, or females with different allelic inactivation, there is a strong correlation between the effect on autoimmune disease and the representation of Treg cells expressing the GFP-FoxP3 protein, indicating that $Foxp3^{fgfp}$ Treg cells are directly involved in altering the course of autoimmune diseases described above.

Th17 Cells in K/BxN.Foxp3^{fgfp} Mice

Th17 cells play a central role in K/BxN arthritis, most directly by modulating the amounts of arthritogenic anti-GPI (Jacobs et al., 2009; Wu et al., 2010). Given the low anti-GPI in K/BxN.Foxp3^{fgfp} mice, we assessed the Th17 cell population in these mice. K/BxN.Foxp3^{fgfp} male mice showed a significant decrease in the frequency of Th17 cells in the small intestine lamina propria (SI-LP) relative to control K/BxN.Foxp3^{igfp} mice (Figure 3A). Preliminary data from NOD.Foxp3^{fgfp} mice follow a similar trend. This difference could be due to an intrinsic defect in Th17 cell differentiation (conceivable given the notion that interactions between FoxP3 and RORyt control the differential toward Th17 or iTreg cells [Zhou et al., 2008]) or to stronger suppression of IL17 production by Treg cells expressing the GFP-FoxP3 protein. We tested the former by using an in vitro Th17 cell differentiation system. To control for interwell variation or indirect effects, we mixed congenically marked naive T cells from B6.CD45.1 and B6.Foxp3^{fgfp} (CD45.2) mice and cultured them together under Th17 cell skewing conditions (Figure 3B). In cultures lacking IL-6, FoxP3+ cells were similarly induced in Foxp3^{fgfp} or Foxp3^{wt} cells (Figure 3B, left panels). IL-17producing cells were induced by IL-6 at similar frequencies in *Foxp3^{fgfp}* or *Foxp3^{wt}* cells, at either concentration of TGF- β , indicating that there is no intrinsic defect of Th17 cell differentiation. We also searched for a Th cell bias in gene expression profiles of unstimulated Tconv cells from NOD or B6.Foxp3^{fgfp}. No bias in typical Th1, Th2, or Th17 cell transcriptional signatures were

Immunity

Different Treg Cell Functions in Autoimmunity



Figure 4. Elevated FoxP3 Expression in Foxp3^{fgfp} Treg Cells

(A) Anti-FoxP3 staining profiles of CD3⁺CD4⁺ cells from different organs of K/BxN.*Foxp3^{fgfp}* male or WT littermates (shaded area is profile from isotype control). Data are representative of three independent experiments.

(B) FoxP3 mean fluorescence intensity (MFI) of splenic Treg cells on three different backgrounds. Each dot represents an individual mouse, and values are normalized to the mean FoxP3 MFI of WT mice in each experiment.

(C) FoxP3 MFI for LN and visceral fat from 40-week-old B6.Foxp3^{fgfp} mice.

(D) Foxp3 mRNA levels in CD4⁺GFP⁺ splenic Treg cells from Foxp3^{fgfp} or WT male mice on two different backgrounds.

observed (Figure S2), indicating that the defective IL-17 induction is only revealed in challenged conditions, such as those of the K/BxN LP.

Altered Characteristics of Foxp3^{fgfp} Treg Cells

The impact of GFP-FoxP3 on differentiation of several Treg cell compartments and the correlation between GFP-FoxP3 expression and autoimmune disease suggested that the chimeric protein might modify particular regulatory aspects or phenotypic characteristics in Treg cells, and thereby impact arthritis or diabetes progression. To elucidate these mechanistic underpinnings, we analyzed several aspects of Treg cell phenotype and function.

The FoxP3 mean fluorescence intensity (MFI) was increased by 2-fold in *Foxp3*^{fgfp} Treg cells in K/BxN males (Figure 4A), evident from early Treg cell differentiation in the thymus. This increase was also present on the B6 and NOD genetic backgrounds (Figure 4B) and was equivalent in males and females. The FoxP3 chimeric protein was also overrepresented, to a less marked degree, in Treg cells from visceral fat and in the pancreatic infiltrate of NOD mice (Figure 4C). This overexpression of FoxP3 was not reflected at the mRNA level (Figure 4D), suggesting that the increase in FoxP3 reflected an effect on the stability of the protein, perhaps through different susceptibility to posttranslational modifications. At any rate, it is clear that the addition of GFP does not destabilize FoxP3.

We then tested the functional activity of *Foxp3^{fgfp}* Treg cells. In the conventional in vitro Treg cell suppression assay, *Foxp3^{fgfp}* Treg cells showed a small increase in suppressor activity (Figure 5A), consistent with the results of Fontenot et al. (2005), who also observed a small shift. This difference was observed only when responder T cells were activated in the presence of irradiated antigen-presenting cells (APCs), given that direct activation of responder T cells, with a plate-bound anti-CD3 antibodies or anti-CD3 and anti-CD28 conjugated beads, did not reveal this enhanced suppression (data not shown). The limited difference in suppressive activity in vitro was clearly not sufficient to account for the divergent effects on the course of arthritis and diabetes, which could be explained by modifications in the balance of different effector functions of Treg cells. To test this hypothesis, we cultured naive T cells under Th1, Th2, and Th17 cell-skewing conditions in the absence or presence of GFP-FoxP3 or IGFP-FoxP3 Treg cells. Transcripts of the key indicator cytokines (*Ifng*, *II17a*, and *II4*) were quantitated by RT-PCR so that specific Th cell-subset differentiation could be determined. Expression of *Ifng* and *II4* were equally suppressed by both GFP- and IGFP-FoxP3 Treg cells (Figure 5B), but GFP-FoxP3 Treg cells were significantly more efficient at blocking Th17 cell differentiation than their IGFP counterparts. This greater efficiency may explain the decrease in SI-LP Th17 cells in K/BxN.*Foxp3^{fgfp}* animals.

To further shed light on the differences between Foxp3^{fgfp} and WT Treg cells, we compared their transcriptional profiles on gene expression microarrays. To properly compare Treg cell populations, we sorted to high purity CD3⁺CD4⁺GFP⁺ (Treg) and CD3⁺CD4⁺GFP⁻ (Tconv) cells from both Foxp3^{fgfp} and Foxp3^{igfp} mice. We performed this comparison on both the B6 and NOD inbred backgrounds to generate independent data sets and to avoid potential confounders from the strong inflammatory alterations in the K/BxN context. The expression plots of Figure 6A, which compare Treg and Tconv cells and highlight the canonical Treg cell signature (Hill et al., 2007), give a broad perspective and show that GFP⁺ cells in B6.Foxp3^{fgfp} mice are indeed Treg cells, with the usual complement of over- and underexpressed transcripts, consistent with the results of Fontenot et al. (2005). Next, we sought finer differences between Foxp3^{fgfp} and Foxp3^{igfp} Treg cells by direct comparison of Treg cell profiles in both strains (Figure 6B). Treg cells from Foxp3^{fgfp} and Foxp3^{igfp} were very similar, with only 74-151 transcripts overexpressed in Foxp3^{fgfp} Treg cells at an arbitrary threshold of 1.5-fold (for comparison, the experimental noise estimated by Monte Carlo randomization and sampling randomization was 60 and 197 hits, respectively, at the same threshold). Many of the transcription factors that were key in establishing the Treg cell signature were equivalently expressed (green dots in Figure 6B). In contrast, 39 of these differential transcripts showed a comparable deviation when the Foxp3^{fgfp} versus Foxp3^{igfp} comparison was made on both the B6 and NOD backgrounds, providing cross-confirmation from independent data sets (only 6.54 overlaps on average in randomized data sets, $p < 10^{-4}$). Further substantiating the significance of these discrete differences, Foxp3^{fgfp}-differential transcripts were not



Immunity

Different Treg Cell Functions in Autoimmunity



Figure 5. Enhanced Treg Cell Function Observed in Foxp3^{fgfp} Treg Cells

(A) In vitro suppressive ability of CD4⁺CD25⁺ Treg cells from B6.*Foxp3^{/gfp}* or WT littermates, titrated at different ratios in cocultures with CD4⁺ Tconv responder cells and APCs. Data represent mean proliferation ± SD of three independent experiments.

(B) Th17 cell differentiation suppressed by GFP-FoxP3 (FGFP) and FoxP3-ires-GFP (IGFP) Treg cells. *Ifng*, *II17a*, and *II4* mRNA expression levels were assessed by quantitative RT-PCR.

a random assortment of transcripts but included a number of genes of established relevance to Treg cells (Figure 6C): effector molecules (*ll10*, *Ctla4*, and *Fgl2*), cell-surface receptors (*Klrg1* and *lcos*), migration factors (*ltgae*, *Ccr2*, *Ccr5*, and *Cxcr3*), and transcription factors (*Prdm1*, *Maf*, and *Ahr*). This signature included several transcripts typically overexpressed in the CD103⁺KLRG1⁺ Treg cell subset (Feuerer et al., 2010). These differences in KLRG1, CD103, and CTLA4 expression were confirmed by flow cytometry in *Foxp3^{fgfp}* heterozygote K/BxN and NOD females, which allow a direct comparison in the same mouse of Treg cells expressing WT versus chimeric FoxP3 (Figure 6D).

We then examined whether this differential representation overlapped with any of the subsignatures that characterize Treg cell subphenotypes, in particular those linked to STAT3 and IRF4, which are associated with the ability of Treg cells to control Th17 cell- and Th2 cell-related functions. We hypothesized that the over-riding suppression of anti-GPI responses in the arthritis model, or to the higher efficacy at suppressing IL17 responses, might be due to one of these sub-signatures. Using the IRF4- or STAT3-dependent gene-sets previously defined in mutant Treg cells (Zheng et al., 2009; Chaudhry et al., 2009), we observed no bias for STAT3-dependent transcripts (data not shown) but there was a significant overrepresentation of IRF4-dependent transcripts in *Foxp3^{fgfp}* Treg cells, on both B6 and NOD backgrounds (Figure 6E). Thus, Treg cells expressing the chimeric FoxP3 do not show a skewing of the entire Treg cell signature, but only a very focused bias, which overlaps with the imprint of IRF4, previously associated with the control of T helper activity and antibody production.

Altered Protein-Protein Interactions between GFP-FoxP3 and Transcriptional Cofactors

This limited and focused effect of GFP-FoxP3 on the Treg cell signature suggested that the insertion of eGFP into FoxP3 might affect its physical interaction with some of its functional cofactors. We thus performed coimmunoprecipitation experiments with Treg cell extracts from $Foxp3^{fgfp}$ and matched control littermates or $Foxp3^{igfp}$ mice. FoxP3 was immunoprecipitated from nuclear lysates, and associated factors were detected by

SDS-PAGE immunoblotting. We first tested the association of FoxP3 with FoxP1, a heterodimer formation known to occur via the leucine-zipper region (Lopes et al., 2006; Li et al., 2007b) and thus presumably away from the GFP insertion site. Coimmunoprecipitation of FoxP1 was equivalent with both FoxP3 and GFP-FoxP3 (Figure 7A), indicating that the overall structure of GFP-FoxP3 was not grossly perturbed. In contrast, the interaction with the transcription factor HIF1-a, recently suggested to antagonize Treg cell differentiation by promoting FoxP3 proteasomal degradation (Shi et al., 2011; Dang et al., 2011), was almost completely abrogated in GFP-FoxP3 relative to WT FoxP3 (Figure 7B); this loss of interaction may plausibly account for the increased amount of FoxP3 protein observed (Figure 4A). The interaction of FoxP3 with IRF4 was tested by coimmunoprecipitation with anti-IRF4, revealing a higher amount of FoxP3-IRF4 complexes in Foxp3^{fgfp} Treg cells relative to control cells (Figure 7C), consistent with the overrepresentation of IRF4dependent gene transcripts. In the course of these experiments, we also observed that IRF4 protein expression itself is higher in Foxp3^{fgfp} Treg cells (Figure 7D), which may contribute to the elevated IRF4-GFP-FoxP3 interaction.

DISCUSSION

The observations reported here imply that perturbations in Treg cell phenotype and functional characteristics can affect autoimmune diseases in a diametrically opposite manner. These can be traced to a discrete genomic signature, identifying candidates for this biased function, and to perturbations in the interaction between FoxP3 and transcriptional cofactors. These results indicate that specific modifications of FoxP3 and of its interactions may be at play during the unfolding of autoimmune diseases and could serve as a basis for therapeutically modulating Treg cell function in a qualitative manner.

From a practical standpoint, these results need to be taken into consideration in the interpretation of some experiments performed with the $Foxp3^{fgfp}$ line in recent years. $Foxp3^{fgfp}$ reporter mice have been used by a large number of investigators to track Treg cells. In some cases we would anticipate the discrete phenotypic and transcriptional perturbations reported

Immunity

Different Treg Cell Functions in Autoimmunity





Figure 6. Biased Gene Expression in *Foxp3^{fgfp}* Treg Cells

Gene expression profiles were generated by microarray of Treg and Tconv cells from B6.*Foxp3*^{/g/p} males, with parallel profiling from B6.*Foxp3*^{/g/p} as a reference. (A) Comparison of expression values in Treg versus Tconv splenocytes from *Foxp3*^{/g/p} and *Foxp3*^{/g/p} B6 males. The canonical Treg cell signature is highlighted in red (Treg cell-upregulated transcripts) and blue (Treg cell-downregulated transcripts).

(B) Comparison of expression values in *Foxp3*^{rg/p} and control *Foxp3*^{rg/p} Treg splenocytes, on B6 and NOD backgrounds. Genes concordantly overexpressed in *Foxp3*^{rg/p} relative to *Foxp3*^{rg/p} in both backgrounds are highlighted in red. Transcription factor genes are represented in green.

(C) Heatmap representation of transcripts over-represented in *Foxp3^{fgfp}* on both backgrounds.

(D) Flow cytometric confirmation of CTLA-4, CD103, and KLRG1 overexpression in CD4⁺FoxP3⁺ Treg cells from spleens of *Foxp3^{rg/p}* heterozygote females, on the K/BxN and NOD backgrounds. The values shown are the percent CD103 or KLRG1-positive cells within the GFP-positive or -negative fraction of Treg cells (mean ± SD of eight mice).

(E) Overrepresentation of the IRF4 Treg cell signature: The ratio of expression in $Foxp3^{g/p}$ versus $Foxp3^{g/p}$ of IRF4-responsive transcripts is shown (log2 scale) for both B6 and NOD data sets. The p value is calculated with a χ^2 test for departure from a null hypothesis of random distribution.

here to have little or no impact. On the other hand, the insertion does have pleiotropic effects, given that it influences Treg cell lineage commitment, FoxP3 expression, and the interaction with several transcriptional cofactors. The GFP-FoxP3 chimera

might be expected to perturb experimental situations dependent on particular facets of Teff cell responses and sensitive to the variation in Treg cell subphenotypes, such as the NOD or K/BxN autoimmune models analyzed here.



Immunity

Different Treg Cell Functions in Autoimmunity



Figure 7. GFP-FoxP3 Differentially Binds Transcriptional Cofactors

(A) Association of FoxP3 with FoxP1 determined by coimmunoprecipitation. Anti-FoxP3 was used for immunoprecipitating FoxP3 from nuclear lysates of CD4⁺CD25⁺ Treg cells from B6.*Foxp3^{fgfp}* or WT mice, and immunoblots were probed for FoxP1 (anti-FoxP3 as control).
(B) Nuclear lysates of B6.*Foxp3^{gfp}* and B6.*Foxp3^{igfp}* CD25⁺ Treg cells were immunoprecipitated with anti-FoxP3 or control IgG and probed with anti-HIF1-α (anti-FoxP3 and anti-β-actin as controls).

(C) Anti-IRF4 was used for immunoprecipitating IRF4 from nuclear lysates CD4⁺CD25⁺ Treg cells from B6.*Foxp3^{fgfp}* or WT mice and immunoblotted for FoxP3. (D) Immunoblot analysis of IRF4 from nuclear lysates of CD4⁺CD25⁺ Treg cells from B6.*Foxp3^{fgfp}* or WT mice; three independent experiments are shown.

From the standpoint of autoimmune diseases, the dichotomous outcome is consistent with the different effector mechanisms involved in NOD diabetes and K/BxN arthritis. Pathogenesis in the former case involves inflammatory infiltration of the target organ directly by autoreactive Th1 cell-like T cells, and it is independent of IL-4 (Wang et al., 1998; Katz et al., 1995; Hung et al., 2005). Although the impact of IL-17 on NOD diabetes has yet to be conclusively established, there are several indications that IL-17 is protective, as demonstrated in several reports showing that mice with high amounts of IL-17 induced by helminth infection, segmented filamentous bacteria (SFB) or NADPH oxidase deficiency are protected from diabetes (Lau et al., 2011; Nikoopour et al., 2010; Tse et al., 2010; Kriegel et al., 2011). In the K/BxN model, in contrast, pathology is due to overwhelming T cell help to B cells, in a process strongly dependent on both IL-4 and IL-17 (Ohmura et al., 2005; Wu et al., 2010). Treg cells in Foxp3^{fgfp} mice are the genomic opposite of IRF4-deficient Treg cells, which are primarily defective in controlling Th2- or Th17-linked B cell responses, resulting in a pathology dominated by uncontrolled production of autoreactive Ig (Zheng et al., 2009): the discrete signature whose expression was lost in the IRF4-deficient cells proved overexpressed in $Foxp3^{fgfp}$ Treg cells. Correspondingly, the in vitro assay showed an enhanced ability of $Foxp3^{fgfp}$ Treg cells to suppress IL-17 production, but not IL-4 (although the assay may have been saturated). This heightened ability of $Foxp3^{fgfp}$ Treg cells to suppress Th17 cell differentiation would translate as more effective suppression of anti-GPI autoantibodies and arthritis in vivo.

One might speculate that imbalances in the ability of Treg cells to suppress different facets of effector cell responses may occur naturally and are involved in the determinism of autoimmune diseases. The consensus is that neither diabetes nor arthritis patients have generic defects in Treg cell numbers or basic functionality. However, more focused perturbations in their flavor of suppressor activity may contribute to arthritis or diabetes susceptibility, conferred by genetic variation or environmental exposure.

There is an interesting parallel between the effects reported here and those of gut-resident microbes. We have recently reported that SFB enhance K/BxN arthritis but protect NOD mice

Immunity

Different Treg Cell Functions in Autoimmunity



from diabetes (Wu et al., 2010; Kriegel et al., 2011), a mirror image of the effect of GFP-FoxP3. In this vein, we have noticed that the protection from arthritis conferred by *Foxp3*^{fgfp} Treg cells can be more or less marked in different animal facilities (less dramatic in conditions where the disease is inherently more severe). Variations in IL-17 may be the common link, but one might speculate that SFB also acts by influencing Treg cell subphenotypes.

Underlying these disease changes are the subtle but highly evocative alterations detected in the transcriptome of Foxp3^{fgfp} Treg cells. Of particular interest is the strong overlap with the IRF4-dependent gene set determined by Zheng et al. (2009). This IRF4 gene signature includes several of the "usual suspects" among effector molecules (CTLA4, TIGIT, ICOS, and FGL2). It also includes transcription factors such as AHR, BLIMP1 (encoded by Prdm1), and Maf, which control each other as well as some of the same targets (Apetoh et al., 2010; Marshall et al., 2008). The IRF4-to-BLIMP1 connection has been previously noted as key elements of a genetic regulatory module in B cell differentiation (Sciammas et al., 2011) and in Treg cells (Cretney et al., 2011). Fittingly, we found a slight positive bias of the BLIMP1 signature defined by Cretney et al. However, this bias was less pronounced as that of the IRF4 signature, and because Prdm1 transcripts are themselves elevated, the inference is that the GFP-FoxP3 protein impacts on this regulatory module at the level of IRF4 or higher.

Underlying these genomic alterations, probably, are the altered interactions of FoxP3 with its transcriptional partners, as shown here and by Bettini et al. (2012). Modifying FoxP3 by insertion of the 238 amino acids of GFP at the N-terminus might be expected, by steric hindrance, to perturb physical interactions occurring through N-terminal motifs of FoxP3 or in its 3D vicinity, but not others involving distant domains or a different face of the folded protein. The GFP insert has no effect on dimerization with FoxP1, which occurs via leucine zipper domains, some distance away from the N-terminus; correspondingly, interaction with NF-AT via the FKHR domain (Wu et al., 2006) is not affected. But interaction with HIF1-a (this work), Eos, HDAC7, and TIP60 (Bettini et al., 2012) are reduced or abolished. HIF1-a has recently been shown to directly bind FoxP3, resulting in its proteasomal degradation, and thus affecting Treg cell differentiation (Shi et al., 2011; Dang et al., 2011). This loss of HIF1-a-FoxP3 interaction, plausibly due to steric hindrance from the bulky domain of GFP, is consistent with the higher levels of FoxP3 in FoxP3^{fgfp} Treg cells.

How the GFP insert would enhance the interaction with IRF4 is less immediately obvious. Some of this increased representation may simply be due to the increased levels of IRF4 in the cell, although this increase (20%–40% by densitometry) may not be sufficient to account for the full increase in FoxP3-IRF4 complex. A simple integrative interpretation is that HIF1- α and IRF4 partially compete for binding sites on FoxP3, with the inability of GFP-FoxP3 to interact with HIF1- α facilitating IRF4 binding (indeed, IRF4 and FoxP3 synergize to activate IRF4 transcription; data not shown). Tripartite molecular interactions between HIF1- α , IRF4, and FoxP3 may also be involved (although interaction between HIF1- α and IRF4 has not been reported, HIF1- α is stabilized when bound to herpes-virus-derived viral IRF3, which shares significant homology to cellular IRF4 [Shin et al., 2008]).

An alternative possibility is that posttranslational modifications of FoxP3, mapping to the N-terminus or indirectly affected by the presence of the GFP insertion, would condition FoxP3's interactions with IRF4. For instance, acetylation of the N-terminal region of FoxP3 results from balanced HAT and HDAC activities (Samanta et al., 2008; Li et al., 2007a). These would very likely be affected by the neighboring insertion, thus indirectly affecting IRF4 binding.

In summary, there is a strong connection between the different facets of these analyses, linking enhanced FoxP3-IRF4 interactions to higher expression of IRF4-dependent Treg cell genes, then to stronger suppression of Th2 and Th17 cell-linked functions and autoimmune disease. It will be important to position these in the broader context of a molecular map of FoxP3's interactions, but these results already open the way to investigations of FoxP3-related genomics in human patients and avenues for therapeutic modulation.

EXPERIMENTAL PROCEDURES

Mice and Autoimmune Evaluation

Foxp3^{igfp} mice were provided by V. Kuchroo. The *Foxp3*^{igfp} (aka *Foxp3*^{tm2Ayr}) trait was crossed for generating K/BxN.*Foxp3*^{igfp}, NOD/LtJ.*Foxp3*^{igfp}, C57BL/6.*Foxp3*^{igfp}, mice (>8 generations on both backgrounds), which were bred and maintained in SPF facilities at Harvard Medical School. Arthritis scores, ankle thickness measurements, and determination of anti-GPI titers were as described (Monach et al., 2008). Mice on the NOD background were monitored biweekly for urine glucose, with confirmation of diabetes by blood glucose determination; mice were considered diabetic with two consecutive readings of blood glucose > 250 mg/dL. All experiments were done with protocols approved by Harvard Medical School's Institutional Animal Care and Use Committee (IACUC protocol 02954 and 3024).

Treg Cell Isolation from Nonlymphoid Tissue

For intestinal lamina propria analysis, mesenteric fat tissue was removed, and the intestine was opened longitudinally, washed in ice-cold PBS, and cut into 1 cm pieces; both were incubated in 25 ml DMEM containing 5 mM EDTA, 0.145 mg/mL DTT for 40 min at 37°C at a rotation speed of 200 rpm. After incubation, the epithelial cell layer was removed by vortexing and passing through a 100 μ m cell strainer. The remaining intestinal pieces were washed in PBS, cut into 1 mm² pieces with scissors, and digested in 25 ml of DMEM supplemented with 1 mg/mL Collagenase D (Roche), 0.15 mg/mL DNase I (Sigma), and 200 ng/mL liberase TL (Roche), at 37°C for 20 min with rotation (200 rpm), then vortexed for 1 min and passed through a 100 μ m cell strainer.

For Treg cells from visceral adipose tissue, blood was flushed from the organs by perfusion of PBS through the portal vein and the heart ventricle, and epididymal adipose tissue was removed, cut into small pieces, and digested for 20 min at 37°C with collagenase type II (Sigma) in DMEM. Cell suspensions were then filtered through a sieve, and the stromovascular fraction was harvested by centrifugation.

In Vitro Suppression Assay

Sorted splenic Teff cells (CD4⁺GFP⁻) were cultured, with or without added Treg cells, for 72 hr in RPMI 1640, 10% FCS, 2 mM L-glutamine, penicillin/ streptomycin at 2.5 × 10⁵ cells/well in round-bottom 96-well plates, supplemented with 1 × 10⁵ APCs and 1.5 µg/mL anti-CD3. Cell proliferation was measured by incorporation of H³-thymidine (1 µCi added in the last 18 hr of culture).

In Vitro Suppression of Th Cell Differentiation

Splenic naive T cells (CD4⁺CD25⁻CD44^{lo}CD62L^{hi}) from B6 mice were sorted and cultured in complete culture medium at 1 × 10⁵ cells/well in Th1 (anti-CD3/CD28 beads + 0.4 ng/mL of IL12), Th2 (anti-CD3/CD28 beads + 4 ng/mL II4), or Th17 (anti-CD3/CD28 beads + IL6; 20 ng/mL and TGF β ;

Different Treg Cell Functions in Autoimmunity

PRESS

2 ng/mL) cell-skewing culture conditions in the presence or absence of *Foxp3^{/gfp}* or *Foxp3^{/gfp}* Treg cells at a 1:1 Teff/Treg ratio. After 66 hr in culture, RNA was extracted from flow-sorted Teff cells (CD4⁺GFP⁻) for quantitative rtPCR (TaqMan).

In Vitro Th17 and Treg Cell Differentiation Assay

Splenic naive T cells (CD4⁺CD25⁻CD62L^{hi}) from B6.*CD45.1* or B6.*Foxp3^{fgfp}* (CD45.2) mice were purified by flow sorting and cocultured at a 1:1 ratio under Th17 cell-skewing conditions: 1 × 10⁶ cells re-suspended in complete culture media and seeded into wells from 48 well plates coated with anti-CD3 (2 µg/mL) and supplemented with soluble anti-CD28 (2 µg/mL), IL-6 (30 ng/mL) and TGF β (5 or 25 ng/mL). At 96 hr, cells were washed and cultured at 37°C for 4 hr with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma), 1 mM ionomycin (Sigma), and BD GolgiPlug (1:1000 dilution), then analyzed for IL17a and FoxP3 expression by flow cytometry after intracellular staining.

Microarray Analysis

Duplicate samples of Tconv (CD3⁺CD4⁺GFP⁻) and Treg (CD3⁺CD4⁺GFP⁺) splenocytes were double-sorted to achieve > 99.0% purity, from 6 weeks old male *Foxp3^{rg/p}* and *Foxp3^{rg/p}* mice (B6 and NOD backgrounds). Cells were collected directly into Trizol. RNA was labeled and hybridized to Affymetrix Mouse Genome M1.0 ST microarrays. Raw data were back-ground-corrected and normalized with the RMA algorithm in the GenePattern software package (Heng and Painter, 2008). The cell populations analyzed were generated in duplicate. Data were analyzed with the "Multiplot" or "Heatmap" GenePattern modules.

Immunoprecipitation and Immunoblotting

Pooled spleen and LN lymphocytes of Foxp3^{fgfp}, Foxp3^{igfp}, or Foxp3^{wt} B6 mice were magnetically purified with anti-CD25 antibodies and lysed on ice with hypotonic solution (10 mm HEPES, 1.5 mM MgCl₂, 10 mM KCl, and 0.05% NP-40 like/IgePal Ca-630) supplemented with EDTA-free complete protease inhibitors (Roche). Nuclear pellets were subsequently treated with nuclear lysis buffer (20 mM HEPES, 300 mM NaCl, 20 mM KCl, EDTA-free complete protease inhibitor cocktail) and MNase (Nuclease S7; Roche). Chromatin digestion was stopped by adding EDTA to 5 mM, and post-nuclear supernatants were incubated with Protein-G Sepharose beads coupled to anti-FoxP3 antibodies (FJK16, eBioscience; 10 µg/reaction) for 2 hr at 4°C with constant rotation. Bound proteins were eluted by boiling, separated by SDS-PAGE, and electro-transferred to PVDF. After blocking (2 hr in 5% milk/1× PBS 0.02% Tween20), blots were probed overnight with anti-FoxP3 (FJK16, eBioscience), anti-HIF1a (Hif1alpha67, Novus Biologicals), and anti-FoxP1 (Cell Signaling). FoxP3-IRF4 cointeractions used the Nuclear complex co-IP kit (Active Motif). Nuclear extract was immunoprecipitated with 2 μg goat anti-IRF4 (Santa Cruz), captured on magnetic protein G beads, and Foxp3 was detected after SDS-PAGE and immunoblotting.

ACCESSION NUMBERS

The microarray data are available in the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds) under the accession number GSE37605.

SUPPLEMENTAL INFORMATION

Supplemental Information includes two figures and Supplemental Experimental Procedures and can be found with this article online at doi:10.1016/ j.immuni.2012.04.007.

ACKNOWLEDGMENTS

We thank D. Vignali and M. Bettini for discussing their observations with us prior to publication, V. Kuchroo for mice, K. Hattori and A. Ortiz-Lopez for help with mice, J. LaVecchio and G. Buruzula for flow cytometry, J. Ericson and S. Davis for help with microarray analyses and bioinformatics, and C. Laplace for help with the manuscript. This work was supported by grants from the NIH (Al051530, Al065858, and DK092541) and the Juvenile Diabetes Research

Foundation (JDRF) (4-2007-1057) to D.M. and C.B. J.N. was supported by an lacocca Foundation fellowship. J.D. was supported by an NRSA Fellowship, Postdoctoral Training Program in Cancer Immunology (DFCI/NCI: T32 CA007386).

Received: July 19, 2011 Revised: January 12, 2012 Accepted: April 4, 2012 Published online: May 10, 2012

REFERENCES

Apetoh, L., Quintana, F.J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E.J., Sherr, D.H., Weiner, H.L., and Kuchroo, V.K. (2010). The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat. Immunol. *11*, 854–861.

Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011). Induction of colonic regulatory T cells by indigenous Clostridium species. Science *331*, 337–341.

Bandukwala, H.S., Wu, Y., Feuerer, M., Chen, Y., Barboza, B., Ghosh, S., Stroud, J.C., Benoist, C., Mathis, D., Rao, A., and Chen, L. (2011). Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity *34*, 479–491.

Barnes, M.J., and Powrie, F. (2009). Regulatory T cells reinforce intestinal homeostasis. Immunity *31*, 401–411.

Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., and Kuchroo, V.K. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238.

Bettini, M.L., Pan, F., Bettini, M., Finkelstein, D., Rehg, J.E., Floess, S., Bell, B.D., Ziegler, S.F., Huehn, J., Pardoll, D.M., and Vignali, D.A.A. (2012). Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity. Published online May 10, 2012. 10.1016/j.immuni.2012.03.020.

Campbell, D.J., and Koch, M.A. (2011). Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat. Rev. Immunol. *11*, 119–130.

Chaudhry, A., Rudra, D., Treuting, P., Samstein, R.M., Liang, Y., Kas, A., and Rudensky, A.Y. (2009). CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science *326*, 986–991.

Cretney, E., Xin, A., Shi, W., Minnich, M., Masson, F., Miasari, M., Belz, G.T., Smyth, G.K., Busslinger, M., Nutt, S.L., and Kallies, A. (2011). The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat. Immunol. *12*, 304–311.

Dang, E.V., Barbi, J., Yang, H.Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.R., et al. (2011). Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell *146*, 772–784.

Feuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A.B., Benoist, C., Shoelson, S., and Mathis, D. (2009a). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. *15*, 930–939.

Feuerer, M., Hill, J.A., Mathis, D., and Benoist, C. (2009b). Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. *10*, 689–695.

Feuerer, M., Hill, J.A., Kretschmer, K., von Boehmer, H., Mathis, D., and Benoist, C. (2010). Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc. Natl. Acad. Sci. USA *107*, 5919–5924.

Fontenot, J.D., Rasmussen, J.P., Williams, L.M., Dooley, J.L., Farr, A.G., and Rudensky, A.Y. (2005). Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity *22*, 329–341.

Heng, T.S., and Painter, M.W.; Immunological Genome Project Consortium. (2008). The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. *9*, 1091–1094.

Hill, J.A., Feuerer, M., Tash, K., Haxhinasto, S., Perez, J., Melamed, R., Mathis, D., and Benoist, C. (2007). Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity *27*, 786–800.

Immunity

Different Treg Cell Functions in Autoimmunity



Hung, J.T., Liao, J.H., Lin, Y.C., Chang, H.Y., Wu, S.F., Chang, T.H., Kung, J.T., Hsieh, S.L., McDevitt, H., and Sytwu, H.K. (2005). Immunopathogenic role of TH1 cells in autoimmune diabetes: evidence from a T1 and T2 doubly transgenic non-obese diabetic mouse model. J. Autoimmun. *25*, 181–192.

Jacobs, J.P., Wu, H.-J., Benoist, C., and Mathis, D. (2009). IL-17-producing T cells can augment autoantibody-induced arthritis. Proc. Natl. Acad. Sci. USA *106*, 21789–21794.

Katz, J.D., Benoist, C., and Mathis, D. (1995). T helper cell subsets in insulindependent diabetes. Science 268, 1185–1188.

Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., and Campbell, D.J. (2009). The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. *10*, 595–602.

Korganow, A.S., Ji, H., Mangialaio, S., Duchatelle, V., Pelanda, R., Martin, T., Degott, C., Kikutani, H., Rajewsky, K., Pasquali, J.L., et al. (1999). From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity *10*, 451–461.

Kouskoff, V., Korganow, A.S., Duchatelle, V., Degott, C., Benoist, C., and Mathis, D. (1996). Organ-specific disease provoked by systemic autoimmunity. Cell *87*, 811–822.

Kriegel, M.A., Sefik, E., Hill, J.A., Wu, H.J., Benoist, C., and Mathis, D. (2011). Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc. Natl. Acad. Sci. USA *108*, 11548– 11553.

Lau, K., Benitez, P., Ardissone, A., Wilson, T.D., Collins, E.L., Lorca, G., Li, N., Sankar, D., Wasserfall, C., Neu, J., et al. (2011). Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J. Immunol. *186*, 3538–3546.

Li, B., Samanta, A., Song, X., Iacono, K.T., Bembas, K., Tao, R., Basu, S., Riley, J.L., Hancock, W.W., Shen, Y., et al. (2007a). FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA *104*, 4571–4576.

Li, B., Samanta, A., Song, X., Iacono, K.T., Brennan, P., Chatila, T.A., Roncador, G., Banham, A.H., Riley, J.L., Wang, Q., et al. (2007b). FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int. Immunol. *19*, 825–835.

Lopes, J.E., Torgerson, T.R., Schubert, L.A., Anover, S.D., Ocheltree, E.L., Ochs, H.D., and Ziegler, S.F. (2006). Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. J. Immunol. *177*, 3133–3142.

Marshall, N.B., Vorachek, W.R., Steppan, L.B., Mourich, D.V., and Kerkvliet, N.I. (2008). Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetra-chlorodibenzo-p-dioxin. J. Immunol. *181*, 2382–2391.

Monach, P.A., Mathis, D., and Benoist, C. (2008). The K/BxN arthritis model. Curr. Protoc. Immunol., *Chapter 15*, Unit 15.22.

Nikoopour, E., Schwartz, J.A., Huszarik, K., Sandrock, C., Krougly, O., Lee-Chan, E., and Singh, B. (2010). Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J. Immunol. *184*, 4779–4788.

Ohmura, K., Nguyen, L.T., Locksley, R.M., Mathis, D., and Benoist, C. (2005). Interleukin-4 can be a key positive regulator of inflammatory arthritis. Arthritis Rheum. 52, 1866–1875.

Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., and Sakaguchi, S. (2007). Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature *446*, 685–689.

Pan, F., Yu, H., Dang, E.V., Barbi, J., Pan, X., Grosso, J.F., Jinasena, D., Sharma, S.M., McCadden, E.M., Getnet, D., et al. (2009). Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science *325*, 1142–1146.

Samanta, A., Li, B., Song, X., Bembas, K., Zhang, G., Katsumata, M., Saouaf, S.J., Wang, Q., Hancock, W.W., Shen, Y., and Greene, M.I. (2008). TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc. Natl. Acad. Sci. USA *105*, 14023–14027.

Sciammas, R., Li, Y., Warmflash, A., Song, Y., Dinner, A.R., and Singh, H. (2011). An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling. Mol. Syst. Biol. *7*, 495.

Shevach, E.M. (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity *30*, 636–645.

Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., and Chi, H. (2011). HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208, 1367–1376.

Shin, Y.C., Joo, C.H., Gack, M.U., Lee, H.R., and Jung, J.U. (2008). Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 3 stabilizes hypoxia-inducible factor-1 alpha to induce vascular endothelial growth factor expression. Cancer Res. *68*, 1751–1759.

Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid, Y., and Shevach, E.M. (2010). Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J. Immunol. *184*, 3433–3441.

Tse, H.M., Thayer, T.C., Steele, C., Cuda, C.M., Morel, L., Piganelli, J.D., and Mathews, C.E. (2010). NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J. Immunol. *185*, 5247–5258.

Vignali, D.A., Collison, L.W., and Workman, C.J. (2008). How regulatory T cells work. Nat. Rev. Immunol. *8*, 523–532.

Wang, B., Gonzalez, A., Höglund, P., Katz, J.D., Benoist, C., and Mathis, D. (1998). Interleukin-4 deficiency does not exacerbate disease in NOD mice. Diabetes 47, 1207–1211.

Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A.D., Stroud, J.C., Bates, D.L., Guo, L., Han, A., Ziegler, S.F., et al. (2006). FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell *126*, 375–387.

Wu, H.J., Ivanov, I.I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D.R., Benoist, C., and Mathis, D. (2010). Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity *32*, 815–827.

Xiao, Y., Li, B., Zhou, Z., Hancock, W.W., Zhang, H., and Greene, M.I. (2010). Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr. Opin. Immunol. 22, 583–591.

Zheng, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J.M., Chu, T.T., Corcoran, L., Treuting, P., Klein, U., and Rudensky, A.Y. (2009). Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature *458*, 351–356.

Zhou, L., Lopes, J.E., Chong, M.M., Ivanov, I.I., Min, R., Victora, G.D., Shen, Y., Du, J., Rubtsov, Y.P., Rudensky, A.Y., et al. (2008). TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453, 236–240.

Ziegler, S.F. (2006). FOXP3: of mice and men. Annu. Rev. Immunol. 24, 209-226.